Ironwood Pharma (IRWD) Price & Analysis

Q: What was Ironwood Pharmaceuticals’s price range in the past 12 months?

Ironwood Pharmaceuticals lowest stock price was $0.53 and its highest was $5.13 in the past 12 months.

Q: What is Ironwood Pharmaceuticals’s market cap?

Ironwood Pharmaceuticals’s market cap is $311.87M.

Q: When is Ironwood Pharmaceuticals’s upcoming earnings report date?

Ironwood Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 86 days.

Q: How were Ironwood Pharmaceuticals’s earnings last quarter?

Ironwood Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.106 by $0.124.

Q: Is Ironwood Pharmaceuticals overvalued?

According to Wall Street analysts Ironwood Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Ironwood Pharmaceuticals pay dividends?

Ironwood Pharmaceuticals does not currently pay dividends.

Q: What is Ironwood Pharmaceuticals’s EPS estimate?

Ironwood Pharmaceuticals’s EPS estimate is 0.04.

Q: How many shares outstanding does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals has 162,434,130 shares outstanding.

Q: What happened to Ironwood Pharmaceuticals’s price movement after its last earnings report?

Ironwood Pharmaceuticals reported an EPS of $0.23 in its last earnings report, beating expectations of $0.106. Following the earnings report the stock price went up 31.771%.

Q: Which hedge fund is a major shareholder of Ironwood Pharmaceuticals?

Currently, no hedge funds are holding shares in IRWD

Compare

344 Followers

IRWD Stock Chart & Stats

$2.05

<$0.01(0.11%)

At close: Jan 08 4:00 PM EST

$2.05

<$0.01(0.11%)

Day’s Range― - ―

52-Week Range$0.53 - $5.13

Previous CloseN/A

Volume359.32K

Average Volume (3M)1.44M

Market Cap

$311.87M

Enterprise ValueN/A

Total Cash (Recent Filing)$140.41M

Total Debt (Recent Filing)$213.24M

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Feb 12, 2026

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.23

Shares Outstanding162,434,130

10 Day Avg. Volume1,975,296

30 Day Avg. Volume1,437,330

Financial Highlights & Ratios

PEG Ratio-8.00

Price to Book (P/B)-2.34

Price to Sales (P/S)2.01

P/FCF Ratio6.82

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Earnings GuidanceManagement expects the rest of the year to show similar strength as 2Q, with guidance for $260-290M total revenue and adjusted EBITDA greater than $105M reiterated.

Revenue GrowthPrescription demand growth continues to be strong with IRWD highlighting 8% y/y volume growth in 1Q25.

Bears Say

Debt And Financial UncertaintyThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.

Regulatory ChallengesThe FDA requires another confirmatory Phase 3 trial for Apraglutide to validate its efficacy and match previous exposure levels.

Ironwood Pharma News

Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension

The major averages were higher near noon after the U.S. Senate voted on a spending package that would...

8d ago

CNC

Ironwood reports Q3 EPS 24c, consensus 12c

Reports Q3 revenue $122.06M, consensus $75.7M. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand...

8d ago

IRWD

Ironwood raises FY25 revenue view to $290M-$310M from $260M-$290M

Consensus $279.38M. Raises FY25 adjusted EBITDA view to at least $135M from at least $105M. “As part of...

8d ago

IRWD

FDA approves Ironwood’s Linzess for IBS-C in pediatric patients

The U.S. Food and Drug Administration announced it has approved Linzess capsules for pediatric patients 7 years and...

13d ago

IRWD

Ironwood jumps after AbbVie reports Linzess sales beat

Shares of Ironwood (IRWD) are moving higher after its partner AbbVie (ABBV) reported Q3 Linzess sales of $315M,...

17d ago

ABBV

IRWD

Ironwood Pharmaceuticals Reports Strong Q3 2025 Earnings

Ironwood Pharmaceuticals ( ($IRWD) ) has released its Q3 earnings. Here is a breakdown of the information Ironwood...

7d ago

IRWD

Ironwood Pharmaceuticals (IRWD) Q3 Earnings Cheat Sheet

Ironwood Pharmaceuticals (IRWD) is scheduled to report 3rd quarter earnings on 11/06/2025. Regarding Q3 estimates, Wall Street analysts...

14d ago

IRWD

Ironwood Pharma Board Member Resigns for New Role

Ironwood Pharma ( ($IRWD) ) has provided an announcement. On October 7, 2025, Andrew Dreyfus announced his resignation...

1M ago

IRWD

Ironwood Pharma Regains Nasdaq Compliance

Ironwood Pharma ( ($IRWD) ) has provided an announcement. On August 29, 2025, Ironwood Pharmaceuticals announced it has...

3M ago

IRWD

Ironwood Pharmaceuticals Reports Strong Q2 2025 Results

Ironwood Pharmaceuticals ( ($IRWD) ) has released its Q2 earnings. Here is a breakdown of the information Ironwood...

3M ago

IRWD

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Cheat Sheet

Ironwood Pharmaceuticals (IRWD) is scheduled to report 2nd quarter earnings on 08/07/2025. Regarding Q2 estimates, Wall Street analysts...

3M ago

IRWD

Ironwood Pharma Elects Directors at Annual Meeting

Ironwood Pharma ( ($IRWD) ) has shared an update. On June 10, 2025, Ironwood Pharmaceuticals held its Annual...

5M ago

IRWD

Ironwood Pharma Receives Nasdaq Deficiency Letter

Ironwood Pharma ( ($IRWD) ) just unveiled an update. On May 28, 2025, Ironwood Pharmaceuticals received a deficiency...

6M ago

IRWD

Ironwood Pharmaceuticals Reports Q1 2025 Financial Results

Ironwood Pharmaceuticals ( ($IRWD) ) has released its Q1 earnings. Here is a breakdown of the information Ironwood...

6M ago

IRWD

IRWD FAQ

What was Ironwood Pharmaceuticals’s price range in the past 12 months?

Ironwood Pharmaceuticals lowest stock price was $0.53 and its highest was $5.13 in the past 12 months.

What is Ironwood Pharmaceuticals’s market cap?

Ironwood Pharmaceuticals’s market cap is $311.87M.

When is Ironwood Pharmaceuticals’s upcoming earnings report date?

Ironwood Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 86 days.

How were Ironwood Pharmaceuticals’s earnings last quarter?

Ironwood Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.106 by $0.124.

Is Ironwood Pharmaceuticals overvalued?

According to Wall Street analysts Ironwood Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ironwood Pharmaceuticals pay dividends?

Ironwood Pharmaceuticals does not currently pay dividends.

What is Ironwood Pharmaceuticals’s EPS estimate?

Ironwood Pharmaceuticals’s EPS estimate is 0.04.

How many shares outstanding does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals has 162,434,130 shares outstanding.

What happened to Ironwood Pharmaceuticals’s price movement after its last earnings report?

Ironwood Pharmaceuticals reported an EPS of $0.23 in its last earnings report, beating expectations of $0.106. Following the earnings report the stock price went up 31.771%.

Which hedge fund is a major shareholder of Ironwood Pharmaceuticals?

Currently, no hedge funds are holding shares in IRWD

Ironwood Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-13.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for gastrointestinal diseases. The company primarily operates in the biopharmaceutical sector, with a strong emphasis on enhancing the quality of life for patients suffering from conditions such as irritable bowel syndrome and chronic idiopathic constipation. Ironwood's core products include Linzess (linaclotide), a prescription medication that promotes intestinal motility and alleviates abdominal discomfort associated with these conditions.

Ironwood Pharma (IRWD) Earnings & Revenues

Historic Earnings Reports

IRWD Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.92,1.7723076923076921,1.6246153846153846,1.476923076923077,1.3292307692307692,1.1815384615384614,1.0338461538461539,0.8861538461538463,0.7384615384615385,0.5907692307692307,0.44307692307692315,0.2953846153846156,0.1476923076923078,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.92,1.7723076923076921,1.6246153846153846,1.476923076923077,1.3292307692307692,1.1815384615384614,1.0338461538461539,0.8861538461538463,0.7384615384615385,0.5907692307692307,0.44307692307692315,0.2953846153846156,0.1476923076923078,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.92,1.7723076923076921,1.6246153846153846,1.476923076923077,1.3292307692307692,1.1815384615384614,1.0338461538461539,0.8861538461538463,0.7384615384615385,0.5907692307692307,0.44307692307692315,0.2953846153846156,0.1476923076923078,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >